<DOC>
	<DOCNO>NCT01221116</DOCNO>
	<brief_summary>Hypothesis : Treatment levosimendan preserve myocardial function hemodynamics cardiac surgery lead reduce stay intensive care unit</brief_summary>
	<brief_title>Inotropic Treatment With Levosimendan ( SimdaxR ) Heart Surgery</brief_title>
	<detailed_description>Single center , prospective , randomized parallel-group , double-blinded study</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>EF ( ejection fraction ) &lt; 40 % renal failure , liver failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2003</verification_date>
	<keyword>coronary artery disease ,</keyword>
	<keyword>aortic stenosis ,</keyword>
	<keyword>heart failure</keyword>
</DOC>